Skip to main content
. 2021 Apr 22;6(8):e145380. doi: 10.1172/jci.insight.145380

Figure 5. Anti-ceramide 6B5 scFv mitigates radiation GI syndrome mortality.

Figure 5

(A) Delivery (i.v.) of anti-ceramide 6B5 scFv (5 mg/kg) at 24 hours after 15 Gy WBR mitigates small intestinal crypt lethality in C57BL/6 mice measured by the Withers and Elkind assay at 3.5 days after radiation (8). ***P < 0.001, Wilcoxon’s rank sum test with continuity correction. Data are compiled from 3 independent experiments. (B) Anti-ceramide 6B5 scFv (5 mg/kg) delivered (s.c.) at 15 minutes before irradiation (Protection) or at 24 hours after irradiation (Mitigation) prevents the lethal GI-ARS, as determined by increased 30-day survival of C57BL/6 mice exposed to 15 Gy WBR and administered HSCT (3 × 106 cells), as calculated by the product limit Kaplan-Meier method. Numbers in parentheses represent animals/group. P < 0.001 h2A2 (40 mg/kg) or scFv mitigation vs. vehicle, P < 0.01 h2A2 or scFv protection vs. vehicle, 2-sided Fisher’s exact test.